• Disease areas
  • Products
  • Sustainable business
  • Partnering & innovation
  • Careers
  • About us
  • Patient help
  • Healthcare professionals
  • Investors
  • News & media
  • Contact us

Latest news

{{'Fri, 20 Jun 2025 19:30:00 -0400' | dateFormatUsFilter}}

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet

Read more

{{'Fri, 20 Jun 2025 13:30:00 -0400' | dateFormatUsFilter}}

In REACH real-world analysis, a 23% risk reduction in A1C-adjusted three-point MACE was observed for Ozempic® (semaglutide) injection compared to dulaglutide

Read more

{{'Tue, 10 Jun 2025 08:00:00 -0400' | dateFormatUsFilter}}

Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025

Read more

News archive

Career opportunities

Here are our current job openings. If we don’t currently have an opening in your area of interest, we encourage you to create a job agent and candidate profile.

NOVO NORDISK USA

800 Scudders Mill Road
Plainsboro, NJ 08536
Tel: 1-609-987-5800

 

Transparency in Employee Health Coverage:

Aetna
United Healthcare

Helpful links

Contact us Copyright Report a side effect or product complaint

Follow us

Facebook X (Twitter) Instagram

Other offices

Select location
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Privacy Policy
Consumer Health Data Privacy Notice
Cookie Policy
Privacy Request

change